breast cancer - borsht kanker neoadjuvant chemotherapy - neoadjuvante chemotherapie response to therapy - response op therapie 31P Magnetic Resonance Spectroscopy - fosfor Magnetische resonantie spectroscopie MRI- MRI
Conditions
Interventions
none
Sponsors
University Medical Centre Utrecht
Amsterdam Medical Centre
Eligibility
Inclusion criteria
Inclusion criteria: • age of 18 years or older • female breast cancer patients (HER2 negative breast cancer, stage II or III) • selected for neo-adjuvant chemotherapy
Exclusion criteria
Exclusion criteria: • any prior surgery or radiotherapy to the ipsilateral breast • Karnofsky score <= 70, • Pregnant or lactating women • Contra-indications to MRI scanning according to hospitals 7T MRI screening guideline of the UMCU.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main study parameters are the signal ratios of ME/PDE or alternatively PME/Pi as obtained with 31P-MRS that should discriminate between responders and non-responders. Non responders show unchanged or even higher PME/PDE and PME/Pi ratios after the first cycle of chemotherapy whereas (partial) responders show a significant decrease in these ratios. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameters as measured with (DCE-MRI, DWI, CEST-MRI) of the tumor prior to chemotherapy and after the first cycle of chemotherapy: - DCE-MRI: Ktrans and kep values; - DWI: ADC values; - CEST-MRI: magnetisation transfer ratio (MTR) values | — |
Contacts
Public ContactJ.P. Wijnen
University Medical Centre Utrecht, Room number Q 04 4311
Outcome results
None listed